Research & Development: MP0250 (VEGF x HGF) in MM: Additional patient data from ongoing Phase 2 study of MP0250 in combination with Velcade® (PI) support previously observed response rates and duration of treatment MP0250 in combination with osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Zurich-Schlieren, April 16, 2019.  At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, the shareholders of the company approved all motions proposed by the Board of Directors

The MAPLE study used a modified manufacturing process and demonstrated decreased intraocular inflammation Previously reported positive Phase 3 results demonstrated the potential for abicipar to be the first anti-VEGF therapy to maintain initial vision gains in all patients on a true fixed 12-week

Zurich-Schlieren, March 29, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin ®  therapeutics* to treat serious diseases, today announced that the company will present new pre-clinical data highlighting the company’s immuno-oncology and DARPin®

Zurich-Schlieren, March 19, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin ®  therapeutics* to treat serious diseases, today published the invitation to the Annual General Meeting 2019. The Annual General Meeting will be held on Tuesday,

Zurich-Schlieren, March 15, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin ®  therapeutics* to treat serious diseases, today published its audited Financial Results for 2018 and the company’s 2018 Annual Report.

Company to highlight the progress on its clinical DARPin® compounds, discuss MP0310 in its strategic partnership with Amgen and update on the initiation of a research project to explore DARPin® molecules targeting peptide MHC complexes supported by Gilead Zurich-Schlieren, March 11, 2019. 

Company positioned for growth following positive phase 3 abicipar data and validation of DARPin ®  platform through Amgen collaboration Research & Development: MP0310: Molecular Partners and Amgen announced strategic collaboration for clinical development and commercialization of lead IO candidate

Company to highlight recent progress on clinical DARPin ®  compounds, its oncology research strategy and to discuss the strategic collaboration with Amgen on MP0310 Zurich-Schlieren, January 7, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin ®

Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin ®  Molecule, in Combination with Amgen’s Oncology Assets, Including BiTE ®  Molecules Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products   ZURICH-SCHLIEREN, SWITZERLAND